Denali therapeutics inc. (DNLI)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Collaboration revenue:
Collaboration revenue from customers

0

26,678

147,588

135,179

0

129,160

3,484

2,289

0

-

0

0

-

Other collaboration revenue

0

-

-

-

0

-

-

-

-

-

-

-

-

Operating expenses:
Research and development

206,995

193,382

181,740

159,517

159,767

143,183

121,745

109,939

76,809

74,460

0

0

0

General and administrative

49,725

46,480

46,646

44,269

36,089

32,349

26,373

21,308

17,976

15,680

0

0

0

Total operating expenses

256,720

239,862

228,386

203,786

195,856

175,532

148,118

131,247

94,785

90,140

0

0

0

Loss from operations

-230,643

-213,184

-80,704

-68,513

-63,132

-46,372

-144,634

-128,958

-94,144

-90,140

0

0

0

Interest and other income, net

14,772

15,219

14,222

13,033

11,578

10,132

7,974

5,825

3,601

1,955

0

0

0

Loss before income taxes

-215,871

-197,965

-179,386

-187,737

0

-

0

0

-

-

-

-

-

Income tax benefit

-500

-400

-400

-300

0

-

0

0

-

-

-

-

-

Net loss

-215,385

-197,614

-66,056

-55,167

-51,554

-36,240

-136,660

-123,133

-90,543

-88,185

0

0

0

Other comprehensive income (loss):
Net unrealized gain on marketable securities, net of tax

503

999

1,978

2,372

1,619

-281

-1,179

-1,116

-892

5

0

0

0

Comprehensive loss

-214,882

-196,615

-64,078

-52,795

-49,935

-36,521

-137,839

-124,249

-91,435

-88,180

0

0

0

Net loss per share, basic and diluted (usd per share)

-0.55

-0.57

-0.48

-0.61

-0.41

0.84

-0.38

-0.59

-0.26

0.90

-2.14

-2.29

-2.36

Weighted average number of shares outstanding, basic and diluted (in shares)

102,419

96,093

95,859

95,495

94,984

94,362

93,665

92,899

89,560

30,937

10,231

9,670

9,017